Home > Boards > US OTC > Biotechs > Oxford BioMedica PLC (OXBDF)

“Any new therapy is going to start in

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
marcusl2 Member Profile
 
Followed By 2
Posts 429
Boards Moderated 0
Alias Born 01/14/14
160x600 placeholder
marcusl2   Sunday, 11/25/18 04:12:25 AM
Re: None
Post # of 753 
“Any new therapy is going to start in refractory patients. [Although] we can get responses in completely refractory patients, it will likely be better if you can do this at an earlier time,” said Maloney, medical director of cellular immunotherapy at Fred Hutchinson Cancer Research Center and a professor of medicine at the University of Washington. “We’re going to see these start moving to a place where we think about them before people have failed several lines of salvage.”

https://www.targetedonc.com/publications/targeted-therapy-news/2018/September-2018/the-impact-of-car-tcell-therapies-in-dlbcl

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist